Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation

CONCLUSIONS.—: This guideline summarizes the current understanding and hurdles associated with the use of PD-L1 expression and TMB testing for immune checkpoint inhibitor therapy selection in patients with advanced non-small cell lung cancer and presents evidence-based recommendations for PD-L1 and TMB testing in the clinical setting.PMID:38625026 | DOI:10.5858/arpa.2023-0536-CP

Source: Archives of Pathology and Laboratory Medicine - April 16, 2024 Category: Laboratory Medicine Authors: Lynette M Sholl Mark Awad Upal Basu Roy Mary Beth Beasley Richard Walter Cartun David M Hwang Gregory Kalemkerian Fernando Lopez-Rios Mari Mino-Kenudson Ajit Paintal Kearin Reid Lauren Ritterhouse Lesley A Souter Paul E Swanson Christina B Ventura Larissa Source Type: research